Google is a multinational technology company focusing on search engine technology, online advertising, cloud computing, computer software, quantum computing, e-commerce, artificial intelligence, and consumer electronics. Their products address a wide range of use cases, including email, navigation, cloud computing, web browsing, video sharing, productivity, operating systems, cloud storage, language translation, photo storage, video calling, smart home, smartphones, wearable technology, music streaming, and more.

Google

New Enterprise Associates is a prominent venture capital firm focusing on investments in technology and healthcare startups. They help entrepreneurs build transformational businesses across multiple stages, sectors, and geographies. With over $19 billion in cumulative committed capital since the firm’s founding in 1977, NEA invests in technology and healthcare companies at all stages in a company’s lifecycle, from the seed stage through the IPO. The firm's long track record of successful investing includes more than 210 portfolio company IPOs and more than 360 acquisitions.

New Enterprise Associates

Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines to treat patients with serious or life-threatening medical conditions. It creates multiple products on the market and a development pipeline. The company became a member of the Roche Group in 2009. As part of their merger agreement, Roche and Genentech combined their pharmaceutical operations in the United States. Genentech’s South San Francisco campus now serves as the headquarters for Roche pharmaceutical operations in the United States. Genentech’s Research and Early Development section operates as an independent center within Roche.

Genentech

Stephens Investment Management is a boutique investment firm that manages a family of financial products. These products include: Hedge Funds, sector-focused Venture Funds, an Income Fund, a Real Estate Fund, a Fund-of-Funds, and private company Direct Investments. The underlying core to our strategy is based on conducting fundamental research on growing companies and sectors.  They are long-term investors, with a focus on value-priced growth companies. In conducting their bottom-up research, they look for: improving fundamentals, turnaround situations, new management or products, insider buying and other changes in the business that could become an investment catalyst. Their main three sectors of expertise are Technology, Healthcare and Natural Resources.  In addition, Stephens Investment Management acts as a strategic family office for the three family partners.

Stephens Investment Management

For 30 years the _Mohr Davidow Ventures team has invested in early stage technology-based startups that redefine or create large new markets. They believe that emerging information technology innovations are enabling a decade-long opportunity to invest in the “Era of Digital Engagement,” one in which personal, commercial, and public sector interactions of all kinds will be profoundly reengineered to leverage the power of mobile devices, cloud computing, and data analytics.  The Firm seeks to identify and partner with exceptional entrepreneurs who leverage these technologies to build companies where seamless, deep engagement with customers will create billion dollar markets in a number of different verticals. These verticals include: Digital Marketing, Advertising, & Media, Collaborative Enterprise Applications, The Digitization of Education and Health, Digital Financial Services, E‐commerce & Digital Retail Innovation, Mobile/Web‐Powered “LifeTech.” The Firm also has previous investments in the innovative life sciences & genomics space.  Leading companies funded by Mohr Davidow Ventures includes: Agile (Acquired by NYSE: ORCL); Aryaka Networks; Brocade; Coupa; Genomatica; HealthTap; Infusionsoft; Kabbage; nLight; ONI Systems (Acquired by NASDAQ: CIEN); Proofpoint (NASDAQ: PFPT); Rally Software (NYSE: RALY); Rocket Fuel (NASDAQ: FUEL); Rambus; Shutterfly (NASDAQ: SFLY); Ticketfly; Verinata Health (Acquired by NASDAQ: ILMN); and Visible Measures. The Firm has $1.85 billion under management.

Mohr Davidow Ventures

Johnson & Johnson Development Corporation (JJDC) is the venture capital subsidiary of Johnson & Johnson. JJDC is comprised of experts and leaders in the health care and technology venture communities who identify early market indicators, health care trends, and strategic investment opportunities. Unlike traditional venture capital firms, JJDC determines the success of an investment’s performance not only in financial returns, but also in the viability of providing strategic growth options for Johnson & Johnson.  JJDC plays an integral role in the identification of new business opportunities outside of Johnson & Johnson’s traditional portfolio and market presence. JJDC identifies new market opportunities and develops new businesses in emergent health care sectors while also creating support venture investments in alignment with the strategic objectives of Johnson & Johnson operating companies.

Johnson & Johnson Development Corporation

Google Ventures invests in sectors including life sciences, consumer, enterprise, crypto, climate, and frontier technology. With Alphabet as its sole limited partner, Google Ventures focuses on long-term investments. Its operating partners assist startups in design, equity, diversity & inclusion, talent, and engineering and help them connect with Google for technology and expertise. Founded in 2009 as Google Ventures, Google Ventures manages over $8 billion in assets with 400 active portfolio companies in North America and Europe. Some notable investments include Uber, Nest, Slack, GitLab, and One Medical. Google Ventures is based in the San Francisco Bay Area with offices in Cambridge, New York, and London.

Google Ventures

MPM Capital is a healthcare investment firm that invests in companies developing therapeutic technologies in oncology. The company invests in life sciences companies that seek to cure diseases by translating science into clinical outcomes. The company prefers to invest in the biotechnology, healthcare, and life sciences sectors.

MPM Capital

Fidelity is a privately owned investment management firm that serves a wide range of clients. It offers services including IRAs, rollovers, annuities, discount brokerage, retirement planning, estate planning, wealth management, securities execution and clearance, and life insurance. They serve individual investors, businesses, financial advisors, and institutions. The firm manages equity, fixed-income, and balanced mutual funds and invests in public equity and fixed-income markets. It also conducts in-house research to inform its investment decisions.

Fidelity

Lauder Partners, LLC is an entity investing in various realms of the technology field. Lauder invest both directly in companies as well as in funds - both venture and others. Since it primarily invests the capital of Gary Lauder and family members, we don't provide much information to the public.

Lauder Partners

Casdin Capital is a fundamental research investment firm focused on the life sciences and healthcare industry. It manages a long-short equity fund and makes investments in early-stage to late-stage private investments.  Casdin was launched in 2012 by founder and CIO Eli Casdin and as of October 2020 has approximately $2.2 billion in assets under management.

Casdin Capital

Xfund is the early-stage venture firm designed to back lateral thinkers. Partnering with Harvard University and others of the world’s preeminent universities, Xfund looks beyond the stereotypical technical pedigrees to seek out extraordinary people who are being systemically ignored by traditional venture capital: technically-gifted liberal arts entrepreneurs. We believe it’s our responsibility to help these unconventional, high potential founders align their ambition and passion with opportunity we help them create, to build the sort of ground-breaking companies that can create a better tomorrow. Xfund has offices in Palo Alto, California, and in Cambridge, Massachusetts. For more about Xfund, please visit http://www.xfund.com.

Xfund

Frontline BioVentures merged with WuXi Healthcare Ventures to form 6 Dimensions Capital.

WuXi Healthcare Ventures

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in the private companies shaping the future. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 37,000 private placements completed across 400+ companies, EquityZen leads the way in delivering “Private Markets for the Public”.

EquityZen

Illumina Ventures is an independently managed venture fund in a strategic partnership with Illumina. Illumina provides the majority of their capital and access to the expertise and vision of the world's leading genomics solutions provider. They invest primarily in early stage companies, in areas where their expertise and special relationship with Illumina can add value. They typically syndicate with other leading institutional and strategic investors. Focus areas include applications of genomics in life science research, healthcare, agriculture and environmental science, public safety and personal wellness.

Illumina Ventures

Sequoia is a venture capital focused on energy, financial, enterprise, healthcare, internet, and mobile startups. The firm helps a small number of daring founders build legendary companies. It spurs them to push the boundaries of what’s possible. The firm seeks to invest in all sectors with a focus on energy, financials and financial services, healthcare and healthcare services, Internet, mobile, outsourcing, and technology.

Sequoia Capital

Altimeter Capital is a technology-focused investment firm based in Menlo Park, CA and Boston, MA.  Altimeter manages a long/short public equity fund and growth-stage private capital funds.

Altimeter Capital

The Wallenberg Foundations is the collective name for the research-supporting foundations funded by members of the Wallenberg family.

Wallenberg Foundations

Euclidean Capital is an investment firm that invests in individual and family services management.

Euclidean Capital

Founded in 2011, G Squared is aligned with a fundamental shift: venture-backed companies stay private longer. As a result, private companies need both primary capital to continue their growth trajectory and transitional capital to provide liquidity to early investors, current and former employees, and other sellers. Positioned at the crux of this liquidity access challenge, G Squared partners with portfolio companies throughout their lifecycle using a fundamentally different approach than traditional VCs. The company invests in companies that challenge the status quo and demonstrate a clear path to superior returns, partnering with world-class entrepreneurs tackling big problems. G Squared funds have invested in household names such as 23andMe, Coursera, Instacart, Lyft, Pinterest, and Spotify, as well as in the next generation of disruptors, including Asana, Blend, Bolt, Brex, Capsule, Flexport, Impossible Foods, Toast, and Turo.

G Squared

Decacorn is a Singapore domiciled cross-border venture capital fund which curates high impact, globally relevant businesses that have rapid adoption curve and use technology as a defensible moat; businesses that have crossed an inflection point and are led by resourceful founders with a mission to disrupt large market opportunities, either existing or newly enabled, with the aim to make our planet shades better than what we inherited from our parents. We invest in tech-led disruptive innovations from key startup destinations, Singapore, Israel, USA, Estonia, etc., enabling us to benchmark best-in-class mix of technologies and proven business models for high-quality curation that generates superior alpha. Decacorn believes that technology investing involves curating companies that harness key technologies of our time, namely: Robotics & Automation,  Genomics, Energy & Storage, AI & Deep Learning, Blockchain, and Cloud & Edge Computing. We Invest across the spectrum from bootstrapped to growth stage by executing a carefully crafted bar-belled strategy in order to balance the risk with rewards while generating exit opportunities at frequent intervals. In just over 3 years, Decacorn has made two dozen investments and has clocked 5 exits.  Some of Decacorn’s early investments have become unicorns while a few others currently in the mid-stage are expected to join the unicorn club in their next financing round.

Decacorn Capital

Nimble Ventures is a family office that makes venture capital investments. The firm was founded in 2014 and is based in San Francisco, CA.

Nimble Ventures

GlaxoSmithKline is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. The company aims to bring differentiated, high-quality and needed healthcare products to as many people as possible, with its 3 global businesses, scientific and technical know-how, and talented people.  GSK's Pharmaceuticals business has a broad portfolio of innovative and established medicines with commercial leadership in respiratory and HIV. Our R&D approach focuses on science related to the immune system, the use of genetics, and advanced technologies. The Vaccines business has a broad portfolio and innovative pipeline of vaccines to help protect people throughout life. It delivers over two million vaccine doses per day to people living in over 160 countries. The Consumer Healthcare business develops and markets an innovative portfolio of consumer preferred and expert-recommended brands in the Pain relief, Respiratory, Digestive health, Oral Health, Nutrition, and Skin health categories.

GlaxoSmithKline

Cube is the family office founded by the Rancilio family in 2013, after the sale of the espresso machine company founded in 1927 by our grandfather Roberto. The Rancilio family managed its company for three generations, during the course of which it became a leading global espresso producer. After selling the family business, we created Rancilio Cube. Cube focuses on venture, growth and impact investments, and makes both direct and fund investments. With regard to direct investments, we invested in companies such as Lyft (made in 2015, we consider it as our ''cornerstone'' venture/growth investment), Sennder, N26, SpaceX, Airbnb, Wise, 23andme, Uber, Flexport, Deliveroo, SumUp, Capsule, Coursera, Lyst, Omaze, Prodigy Finance, Taboola, Applause, Reef, Rapyd, Logz.io, Tier, Toast, Bnext, Treedom, Casavo and many more.  Cube also makes limited partner investments in international VC funds: examples include Pelion, Earlybird DE, Cherry Venture, Foundation Capital, Khosla, NEA, Lake Star, Hoxton Venture, Hetz, Glilot, Cavalry, Bessemer, Omega, Blue Lion, TCV, Firstmark, Seedcamp, Holtzbrinck, OWL, Better Tomorrow, Zetta, DST, Jackson Square Venture, GSquared, Speedinvest, Target GlobaI, Aspect Ventures, Oxford Science Innovation, Triodos Organic Growth and other funds. From 2022 we are a fully compliant investment company for professional investors. We got an embedded global network, with a particularly deep and wide set of relationships in the Us/European investment and corporate markets. Cube goes out of its way to open up its networks for the benefit of the companies and funds in which it has invested.

Rancilio Cube Sicaf

NewView Capital is a new model venture capital. It spun out of New Enterprise Associates (NEA) in response to evolving market dynamics, including extended exit timelines. NewView Capital has developed a new model in venture capital to drive sustainable growth for entrepreneurs, venture capital firms, and limited partners in this changing venture landscape.

NewView Capital

Pegasus Tech Ventures is a Silicon Valley-based venture capital firm working with emerging technology companies across the world, and specialize in helping entrepreneurs achieve global expansion into North America, Asia, and Europe. Our 100+ person team operates out of offices across 7 different countries and offers a wide range of domain expertise. Pegasus Tech Ventures currently has several multi-million dollar funds under management. We seek to work with world-class management and technical teams that are targeting disruptive opportunities in IT, Health IT, Artificial Intelligence, IoT, Robotics, Big Data, Virtual Reality, Augmented Reality, Quantum Computing, FinTech, and Next Generation Technologies.

Pegasus Tech Ventures

23andMe

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

<div>
 
 Doctor on Demand is an online provider platform that allows users to consult doctors through video, text messages, or phone calls. The company&rsquo;s services include urgent care (24/7 access to doctors), behavioral health, preventive health, and chronic care. It does not currently offer subscription plans and charges on a per-visit basis. Patients can either set up an appointment with a doctor or opt for a doctor on demand, which will direct them to the next available practitioner. Doctor on Demand charges different fees based on the medical specialties. On-demand sessions can also be extended for an additional fee. 
 
 
 In addition to the business-to-consumer (B2C) model, Doctor on Demand also operates a business-to-business (B2B) model, providing a suite of virtual primary care services for the covered beneficiaries of employers and health plans. It was the first telemedicine company to integrate lab testing into its services in 2017. In May 2020, the company expanded telehealth services to the 33 million senior beneficiaries of the Medicare Part B program, becoming the first telehealth operator to do so. Doctor on Demand raised USD 75 million in July 2020 from General Atlantic, bringing the total funding to USD 235.7 million. The company was valued at USD 875 million after the round. The funds are being used to fund the growth and expansion of its virtual care model amidst the increased demand from the Covid-19 pandemic.
 
 
 In March 2021, Doctor on Demand and Grand Rounds entered into a merger agreement to form a new virtual primary care company. The terms of the merger were not disclosed but the transaction is expected to take place within the first half of 2021 subject to regulatory approval.&nbsp;The companies has also signed a definitive agreement to acquire Included Health, a care navigation platform for the LGBTQ+ community in May 2021. This marks the first LGBTQ-specific healthcare platform to be acquired by a leading telehealth provider and would enable Doctor on Demand to enhance its member-centric digital offering by supporting diverse and underserved communities as well as capitalizing on the growing demand for LGBTQ specific offerings.&nbsp;
 
 
 
</div>

Modern tools to train and motivate staff, and bridge emerging skill gaps.

EdTech: Corporate Learning

<div>
 
 Founded by Tony Blair&rsquo;s son Euan Blair as WhiteHat in 2016, Multiverse (formerly Whitehat until January 2021) is a talent accelerator offering an apprentice training, networking, and matching platform. The company matches non-graduate talent with apprenticeship opportunities in professional services and digital roles in UK companies. In partnership with content providers, the company delivers job-relevant training on a one-on-one basis using technology-based tools over the course of an apprenticeship as an alternative to university education. Participants also join an online and offline community of other apprentices. In addition, WhiteHat upskills existing employees to bridge skill gaps.
 
 
 In 
 <a href="https://sp-edge.com/updates/28431">
 April 2024
 </a>
 , Multiverse acquired Searchlight, a provider of AI-powered recruiting and assessment solutions, to use Searchlight's technology to develop new AI products to enhance its professional training services.&nbsp;
 
 
 Key customers and partnerships
 
 
 In March 2021, Multiverse partnered with New College of the Humanities (NCH) to launch a degree-level apprenticeship. The Advanced Data Fellowship allows apprentices to develop their data analysis and data science skills to add value at their workplace. In June 2022, the company reported that it had trained more than 8,000 apprentices via partnerships with 500 companies.&nbsp;&nbsp;
 
 
 Funding and financials
 
 
 In June 2022, the company raised GBP 176 million (USD 220 million) in a Series D funding round co-led by StepStone Group, and previous investors Lightspeed Venture Partners and General Catalyst, with a valuation of USD 1.7 billion. It planned to use the funds to scale its US expansion.
 
 
 In 
 <a href="https://sp-edge.com/updates/15520">
 FY2022,
 </a>
 Multiverse reported a YoY revenue growth of 3x to GBP 27.3 million. The UK operations accounted for 95% of the total revenue and the US operations contributed the balance. The company reported its 6th consecutive year of losses, with net losses rising 30% YoY to GBP 14.2 million due to a rise in administrative spending.
 
</div>

Educational technology plays a pivotal role in driving and enabling the revolution in post-secondary learning

Higher EdTech

Multiverse is an edtech company founded in 2016 by Euan Blair, son of former UK Prime Minister Tony Blair. The company provides professional apprenticeships as an alternative to university education and corporate training. Multiverse matches talented individuals with apprenticeship opportunities at top companies, offering paid, tuition-free programs in areas such as software engineering, digital marketing, and data analytics. These apprenticeships typically last 12-15 months and combine on-the-job training with education.
Multiverse's platform connects apprentices with over 500 partner organizations globally, including major companies like Cisco, Verizon, Google, and Morgan Stanley. The company employs coaches to support apprentices throughout their programs and provide personalized guidance. Multiverse generates revenue by charging employers recruitment fees and training costs. As of April 2023, Multiverse had worked with over 10,000 apprentices globally. The company reported that its programs have created USD 669 million in cost-saving or revenue-generating activities for client companies.
In June 2022, Multiverse raised USD 220 million in Series D funding at a USD 1.7 billion valuation, making it the UK's first edtech unicorn. However, the company has faced financial challenges, reporting a pre-tax loss of GBP 40.5 million for the year ending March 2023, its seventh consecutive year of losses. In October 2023, Multiverse announced a shift in strategy, moving away from school-leaver apprenticeships to focus more on upskilling existing employees at corporate clients. This pivot resulted in over 40 job cuts in its early talent division over a 12-month period.

Multiverse is a tech startup that seeks to provide an alternative to university training. Multiverse ensures young people have access to the best career-focused apprenticeships on offer. Multiverse empowers and supports people to create their own realities as they journey through a fulfilling career. Multiverse is a true alternative to a one-track university route and often uninspiring corporate training.

Doctor On Demand is a video telemedicine company, offering on-demand and scheduled visits with US-licensed healthcare providers via any smartphone, tablet, or computer. It focuses on providing solutions for employers, health plans, retail clinics, and health systems. With solutions for employers, health plans, retail clinics, and health systems, Doctor On Demand is redefining the industry with top-rated customer experience, highest clinical standards, and implementation and customer success directors, as well as 24/7 customer support. The company was founded in 2013 and is headquartered in San Francisco, California.

23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas.

<div> 23andMe is a human genome research company enabling users to study their ancestry, genealogy, and inherited traits. A startup co-founded by Linda Avey and Anne Wojcicki, the wife of Google co-founder Sergey Brin, 23andMe has plans to make the human genome searchable. Brin, along with Google, gave 23andMe $3.9 million as part of a series A in May of 2007. The company was named after the number of chromosome pairs in humans. They aim to help people understand what their genes mean by indexing them and highlighting significant findings. 23andMe allows its clients/users to study their ancestry, genealogy, and inherited traits. The company also markets to researchers and scientists, for whom they provide neatly categorized and easily searchable data. One reason the Google investment in 23andMe made sense, was that this company could enable the search giant to index another facet of the world's information. With the Biotech and Health Care industries growing rapidly, 23andMe could help Google get and maintain a market hold in these already multi-billion dollar areas. </div>

23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation

Real-time collection of patients’ health-related data using any remote patient monitoring device combined with general telemedicine services to reduce readmission rates.

A platform that facilitates the transmission of patient data to different locations for further evaluation and interpretation by medical specialists.

A digital platform that offers specialty care services to address the specific needs of a patient or demographic, including consultations where patients are generally reluctant to meet practitioners face-to-face.

Primary care through virtual consultations for general health-related concerns using a digital platform or mobile app.

Companies developing B2B software solutions for patient engagement, care navigation, practice management, and electronic health records integration to facilitate telehealth services for healthcare providers.

Companies that use GenAI as a core part of their product offering for Telehealth

Leveraging personal data for custom-fit diagnosis and treatment

Precision Medicine

Companies providing genetic tests to identify individuals with high risk or at-risk of having hereditary disease, aid physicians with a diagnosis, and support clinical decision making.

Secure cloud-based platforms and data sharing networks that collect, index, store, and analyze large amounts of health data and patient population data sets from sources including genomic, clinical, wearables, imaging, and population data.

Biopharma and biotechnology companies that develop precision medicine drugs based on novel disease biomarkers present in multi-omic patient population data and genetic insights.

Companies that study intergenomic variations in genes associated with drug response and metabolism to match patients with the appropriate drug and dosage.

Companies that develop an in-vitro medical device or imaging tools and tests that identify genetic mutations for both diagnostic (nature of the disease) and prognostic (likely course of the disease) purposes, allowing providers to match a patient to a specific drug or therapy.

Software analytics platforms that integrate multiple omics datasets (genomics, transcriptomics, proteomics, and metabolomics) to gain insights and support target discovery, drug development, clinical trials, and diagnostics.

ANALYST_QUICK_TAKE

INCUMBENTS_PRESENT

PROMINENT_CATEGORY

<div>
 
 23andMe, a personal genomics and biotechnology company, has entered a research collaboration with Mirador Therapeutics, a precision medicine firm. The partnership will focus on advancing immunology and inflammation-related disease therapy developed by Mirador.
 This collaboration will allow Mirador to utilize a specific set of de-identified genetic and phenotypic data obtained from the 23andMe research database. Such data will be used in conjunction with Mirador's proprietary Mirador360 technology. The main objective of this partnership is to increase target validation and precision of medication. The intention is to move forward the development of transformative precision therapies for chronic immune-influenced inflammatory and fibrotic conditions.
 Mirador Therapeutics specializes in creating first-in-class therapeutics for immunology and inflammation problems. The company employs its unique Mirador360 development engine for this purpose. This technology examines patient molecular profiles to detect and validate genetic associations linked to immuno-fibrotic diseases. Also, it helps in identifying novel therapeutic targets and scrutinizing target-to-target interactions for potential combination therapies. The company focuses on diseases affecting the gastrointestinal tract, lung, and skin.
 
</div> Analyst QuickTake: 
 In <a href="https: 
//sp-edge.com/updates/27838"> March 2024 </a> , Mirador Therapeutics raised USD 400 million in a seed funding round led by ARCH Venture Partners, including initial investments from OrbiMed and Fairmount. The funding was planned to be directed toward developing several therapeutic initiatives focused on immune-mediated inflammatory and fibrotic conditions. Through this partnership, it appears the company is moving ahead with its intentions.

23andMe

Featured Industries

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless